[1st attempt at using the antioxidant dibunol in the acute stage of a myocardial infarct].
Results of dibunol use in 31 patients with progressive myocardial infarction (MI) are presented. The effect of the drug was studied by precardial charting and serial determination of creatine phosphokinase activity, integral rheography and phase analysis of the cardial systole. It was established that in the acute phase of MI, dibunol significantly reduced the ischemic damage to the myocardium and limited the focus of necrosis. Prolonged total intake of the drug throughout the acute period of MI stimulated cardiac activity without a statistically significant improvement in the contractile capacity of the myocardium, however. Patients treated with dibunol in the acute period of MI tended to show a lower frequency of pain recurrences and a decrease in such parameters as the development of heart failure, and/or rhythm disturbances and the mortality rate.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D002084:Butylated Hydroxytoluene / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000517:prevention & control; D011433:Propranolol / Q000008:administration & dosage; D012008:Recurrence; D013315:Stress, Psychological / Q000188:drug therapy
D000975:Antioxidants; D002084:Butylated Hydroxytoluene; D011433:Propranolol
Pervyĭ opyt primeneniia antioksidanta dibunola v ostrom periode infarkta miokarda.